News

PipelineReview.com5h
Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®
AHMEDABAD, India I August 7, 2025 I Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified ...
PipelineReview.com5h
Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan
Kaken will also provide support for the ALPHA-ORBIT Phase 3 trial in Japan, be responsible for regulatory submissions in Japan, and will reimburse Astria for a portion of the costs of the navenibart ...
PipelineReview.com5h
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy
DUBLIN, Ireland I August 06, 2025 I Prothena Corporation plc (NASDAQ:PRTA), announced that Novo Nordisk communicated during their second quarter 2025 earnings ...
PipelineReview.com5h
FDA approves expanded indication for AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in cytokine release syndrome (CRS)
INCHEON, South Korea I August 6, 2025 I Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication ...
PipelineReview.com5h
Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta
SAN FRANCISCO, CA, USA I August 06, 2025 I Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in ECLIPSE 3. All ...
PipelineReview.com5h
US NCI Sponsors Senhwa Biosciences’ Second Program-IND Submitted for Clinical Trial Targeting MYC-Aberrant Lymphoma
TAIPEI, Taiwan and SAN DIEGO, CA, USA I August 7, 2025 I Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class ...
PipelineReview.com1d
Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and ...
LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTM implant technology, showed a positive safety and tolerability profile, along with ...
PipelineReview.com1d
Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference
BOTHELL, WA, USA I August 05, 2025 I Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the presentation of favorable safety and tolerability data from a ...
PipelineReview.com1d
Fapon Biopharma Announces the enrollment of the First Patient in the Phase I Clinical Trial of FP008, A First-in-Class Immunotherapy for Solid Tumors
DONGGUAN, China I August 5, 2025 I Fapon Biopharma, a biotech in developing therapeutic antibodies and fusion proteins, is delighted to announce the ...
PipelineReview.com1d
Epicrispr Biotechnologies Doses First Patient in First-in-Human Clinical Trial of EPI-321 for Facioscapulohumeral Muscular Dystrophy
FDA has granted Fast Track, Rare Pediatric Disease, and Orphan Drug Designation for EPI-321 in FSHD SOUTH SAN FRANCISCO, CA, USA I August 05, 2025 I Epicrispr Biotechnologies, a clinical-stage company ...
PipelineReview.com1d
Polpharma Biologics and Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar PB016
AMSTERDAM, The Netherlands; ZUG, Switzerland & GDAŃSK, Poland I August 05, 2025 I Polpharma Biologics S.A. (“Polpharma Biologics”) announces a global ...
PipelineReview.com1d
Hemispherian Receives FDA IND Clearance for First-in-Class Glioblastoma Therapeutic, GLIX1
OSLO, Norway I August 5, 2025 I Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, today announced ...